UT Health co-authored study shows how cancer patients with COVID-19 react to different treatments

Patients taking Remdesivir had lower mortality rates

A new study conducted by UT Health shows how cancer patients with covid-19 reacted to different treatments
A new study conducted by UT Health shows how cancer patients with covid-19 reacted to different treatments

SAN ANTONIO – A new study co-authored by a UT Health researcher shows how cancer patients with COVID-19 react to different treatments.

According to researchers, the study found new evidence of how cancer patients with COVID-19 react to different treatments, analyzing the treatment of almost 2,200 cancer patients with COVID-19.

US signs contract with Pfizer for COVID-19 vaccine doses

The study found that the cancer patients’ mortality rate was 16%, triple the global average.

Dr. Dimpy Shah said patients taking the anti-viral medication Remdesivir had lower mortality rates. However, those taking other drugs engineered to help fight COVID-19 did not.


About the Author:

Jakob Rodriguez is a digital journalist at KSAT 12. He's a graduate of Texas State University, where he served as the editor-in-chief of the student-run newspaper, The University Star.